mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) is a prevalent complication in kidney transplant recipients.
• LVH is linked to adverse clinical outcomes in this population.
• The impact of immunosuppressive agents on LVH post-transplantation requires investigation.

Purpose of the Study:

• To review existing data on LVH in renal transplantation.
• To evaluate the response of LVH to immunosuppressive treatments.
• To specifically examine the role of mammalian target of rapamycin (mTOR) inhibitors in LVH regression.

Main Methods:

• Literature review of studies on LVH in kidney transplant recipients.
• Analysis of studies assessing LVH changes after immunosuppressive therapy.
• Focus on data concerning mTOR inhibitors and post-transplant cardiomyopathy.

Main Results:

• Recent studies suggest mTOR inhibitors can induce LVH regression in kidney transplant recipients.
• This regression has been observed particularly in patients with post-transplant cardiomyopathy.
• The data indicates a potential therapeutic benefit of mTOR inhibitors for LVH.

Conclusions:

• Mammalian target of rapamycin inhibitors show promise in regressing left ventricular hypertrophy in kidney transplant recipients.
• Further large-scale randomized controlled trials are necessary to confirm these findings.
• The clinical impact of LVH regression on hard endpoints needs to be established.